Retroviral gene transfer of tissue-type plasminogen activator targets thrombolysis in vitro and in vivo

Gene Therapy

Volumn 14, Issue 21, 2007, Pages 1537-1542

  Gong, Y S ^a   Zhang, K L ^a   Jiang, X G ^a   Wang, Z W ^b   Sun, Z Q ^a   Cai, J ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CELL LINE; CELLS, CULTURED; GENE THERAPY; GENETIC VECTORS; HUMANS; MICROSCOPY, ELECTRON; MODELS, ANIMAL; POLYETHYLENE TEREPHTHALATES; PROSTHESES AND IMPLANTS; RABBITS; RETROVIRIDAE; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; VENA CAVA, INFERIOR;

ORYCTOLAGUS CUNICULUS;

EID: 35348917295     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303012     Document Type: Article

References (36)

1. Agarwala S, Kumar S, Berridge J, Mclenachan J, O'Regan DJ. Double valve replacement for acute spontaneous left chordal rupture secondary to chronic aortic incompetence. Journal of Cardiotharacic Surgery 2006; 1: 33.
2. Joseph S, Emanuel R, Sturridge M, Olsen E. Congenital aortic valve disease with rupture of mitral chordae tendinae. Br Heart J 1976; 38: 665-673.
3. Schelbert EB, Vaughan-Sarrazin MS, Welke KF, Rosenthal GE. Hospital volume and selection of valve type in older patients undergoing aortic valve replacement surgery in the United States. Circulation 2005; 111: 2178-2182.
4. Florath I, Albert A, Rosendahl U, Alexander T, Ennker IC, Ennker T. Mid term outcome and quality of life after aortic valve replacement in elderly people: Mechanical versus stentless biological valves. Heart 2005; 91: 1023-1029.
5. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: Final report of the veterans affairs randomized trial. J Am Coll Cardiol 2000; 36: 1152-1158.
6. Oxenham H, Bloomfield P, Wheatley DJ, Lee RJ, Cunningham J, Prescott RJ et al. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. Heart 2003; 89: 715-721.
7. Uchiyama S. New modalities for the treatment of acute cardioembolic stroke. Inter Med 2006; 45: 493-494.
8. Dangas G, Fier C, Ambrose JA. Thrombolytic therapy in acute myocardial infarction. Drugs Today (Barc) 1998; 34: 727-736.
9. Matsuo O. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590-591.
10. Wiman B, Chemielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. The Journal of Biological Chemistry 1984; 259: 3644-3647.
11. Wun TC, Capuano A. Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro. J Biol Chem 1985; 260: 5061-5066.
12. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasninogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990; 265: 109-113.
13. Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol 1990; 110: 155-163.
14. de las Heras N, Cediel E, Oubina MP, Aragoncillo P, Sanz-Rosa D, Lahera V et al. Comparison between the effects of mixed dyslipidaemia and hypercholestero-laemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits. Clin Sci 2003; 104: 357-365.
15. Sakamoto T, Oshima Y, Nakagawa K, Ishibashi T, Inomata H, Sueishi K. Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness. Hum Gene Ther 1999; 10: 2551-2557.
16. Kurihara H, Matsumoto S, Tamura R, Yachiku K, Nakata A, Nakagawa T et al. Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction. Am Heart J 2004; 147: E14.
17. Dopf J, Horiagon TM. Deletion mapping of the Aequorea Victoria green fluorescent protein. Gene 1996; 173: 39-44.
18. Bierhuizen MF, Westerma Y, Visser TP, Dimjati W, Wognum AW, Wagemaker G. Enhanced green fluorescent protein as selectable marker of retroviral-mediated gene transfer in immature hematopoietic bone marrow cells. Blood 1997; 90: 3304-3315.
19. Zhang G, Gurtu V, Kain SR. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res Commun 1996; 227: 707.
20. Mann RM, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper free defective retrovirus. Cell 1983; 33: 149-153.
21. Whitcomb JM, Hughes Sh. Retroviral reverse transcription and integration: Progress and problems. Annu Rev Cell Biol 1992; 8 275-306.
22. Shih CC, Stoye JP, Coffin JM. Highly preferred targets for retrovirus integration. Cell 1988; 53: 531-537.
23. Varmus HE. Retroviruses. Science 1988; 240: 1427-1435.
24. Hori S, Nomuta T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3. Science 2003; 299: 1057-1061.
25. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vector for gene transfer and expression. Methods Enzymol J 1993; 218: 581-599.
26. Cashion LM, Bare LA, Harvey S, Trinh Q, Zhu Y, Devlin JJ. Use of enhanced green fluorescent protein to optimize and quantitate infection of target cells with recombinant retroviruses. Biotechniques 1999; 26: 924-930.
27. Edlund M, Blomback M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagul Fibrinolysis J 2003; 14: 593-598.
28. Madhyastha HK, Radha KS, Sugiki M, Omura S, Maruyama M. Purification of c-phycocyanin from Spirulina fusiformis and its effect on the induction of urokinase-type plasminogen activator from calf pulmonary endothelial cells. Phytomedicine J 2006; 13: 564-569.
29. Edward N. Methods for improving the sensitivity and specifity of the fibrin plate. Clin Path J 1972; 25: 335-337.
30. Eton D, Yu H, Wang Y. Endograft technology: A delivery vehicle for intravascular gene therapy. J Vasc Surg 2004; 39: 1066-1073.
31. Jiang X, Liu X, Zhang K, Xia J, Xiang D, Wu L et al. Experiment study of tissue-type plasminogen activator gene to prevent vein grafts stenosis. Huazhong Univ Sci Technology Med Sci 2006; 26: 314-316.
32. Seltzem SM, Reed MD, Siwik ES. Intra-atrial tissue plasminogen activator infusion for prosthetic valve thrombosis. Catheter Cardiovasc Intero 2006; 67: 139-141.
33. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA et al. Current protocols in Molecular Biology. Greene Publishing Associations: Inc. & John Wiley & Sons, Inc, 1994.
34. Reeves L, Smucker P, Cornetta K. Packaging cell line characteristics and optimizing retroviral titer: The additional gene vector laboratory experience. Hum Gene Ther 2000; 11: 2093-2103.
35. Nishino T, Tubb J, Emerv DW. Partial correction of murine beta-thalassemia with a gamma-retrorirus vector for human gamma-globin. Blood Cells Mol Dis 2006; 37: 1-7.
36. Aflalo ED, Sod-Moriah UA, Potashnik G, Har-Vardi I. Expression of plasminogen activators in preimplantation rat embryos developed in vivo and in vitro. Reprod Biol Endocrinol 2005; 3: 7.